Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

Our senior market strategist explains which ETFs offer exposure to high-powered biotech growth, without T. Rex-sized risk.

This biotech has candidates in late-stage clinical development.

Shares of biotech companies were outpacing the broader market on Thursday. The State Street SPDR S&P Biotech ETF was up 2.7%, compared with the 0.8% gain of the S&P 500. A significant portion of these ...

Carvykti sales surge, MRD FDA guidance speeds label expansion, and strong cash runway. Click for more on LEGN stock.

Today, Jan. 23, 2026, profit taking and fresh glioblastoma survival data weighed on a soaring biotech stock. ImmunityBio ( ...

Local biotech entrepreneurs and investors are seeing signs that the four-year "biotech winter" is finally thawing, though ...

Other useful metrics include insider buying and levels of short activity, which offer stronger predictive signals than ...

Investing.com -- IO Biotech Inc (NASDAQ:IOBT) stock plunged 46.5% Wednesday after the clinical-stage biopharmaceutical company announced it would explore strategic alternatives to maximize stockholder ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

The sector looks overvalued, and retail investors have pumped prices higher.